retatrutide drug retatrutide clinical trials Retatrutide, the next generation of GLP-1 from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage trial, the company announced. In Retatrutide - LeadWest Medical
Description
According to previous studies, patients with diabetes are four times more likely than people with no diabetes to experience severe Long COVID symptoms, but the exact mecahanisms remain unknown, he added

There is currently no confirmed causal link between retatrutide and depression based on published Phase 2 trial data

()

For tirzepatide, 503A (traditional) pharmacies had until February 18, 2025, and 503B (outsourcing) facilities had until March 19, 2025 to stop their GLP-1 production
How Do I Tell Telogen Effluvium from Pattern Hair Loss
